{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:12:47Z","timestamp":1786122767296,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["14\/ICS\/B3042"],"award-info":[{"award-number":["14\/ICS\/B3042"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the prevalence and prognostic significance of the SKY92 gene\u2010expression signature, evaluate minimal\/measurable residual disease (MRD), and identify molecular drivers of high\u2010risk disease in transplant\u2010eligible newly diagnosed multiple myeloma (TE\u2010NDMM) patients in the Republic of Ireland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Baseline genomic risk was assessed using the MMprofiler microarray in 114 TE\u2010NDMM patients. MRD was evaluated 100\u2009days after autologous stem cell transplantation using next\u2010generation sequencing at the International Myeloma Working Group\u2010recommended sensitivity of 10\n                      <jats:sup>\u22125<\/jats:sup>\n                      . Differential gene expression and copy number analyses were performed and compared with digital MLPA and retrospective fluorescence in\u00a0situ hybridisation (FISH).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SKY92 classified 25.4% (29\/114) of patients as high\u2010risk and was associated with inferior progression\u2010free survival and other adverse disease features. MRD assessment achieved 10\n                      <jats:sup>\u22125<\/jats:sup>\n                      sensitivity, although MRD negativity was not associated with SKY92 risk status. High\u2010risk disease demonstrated enrichment of pathways involved in chromosomal stability and DNA repair.\n                      <jats:italic>NUF2<\/jats:italic>\n                      emerged as a key independent prognostic marker, showing strong association with high\u2010risk biology and identifying a potential molecular driver of aggressive disease. Copy number abnormality detection showed high concordance between MMprofiler, digital MLPA, and retrospective FISH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This first characterisation of SKY92\u2010defined high\u2010risk multiple myeloma in Ireland supports integrated genomic profiling for clinical risk stratification and identifies\n                      <jats:italic>NUF2<\/jats:italic>\n                      as a promising candidate driver, demonstrating that deep profiling of high\u2010risk disease may help to discover new targets for this challenging entity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70282","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:57:42Z","timestamp":1786103862000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>SKY92<\/scp>\n                    Identifies High\u2010Risk Newly Diagnosed Multiple Myeloma With Inferior Progression\u2010Free Survival and Implicates\n                    <scp>NUF2<\/scp>\n                    as a Candidate Driver"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-3047","authenticated-orcid":false,"given":"Roisin M.","family":"McAvera","sequence":"first","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"},{"name":"Molecular Pathology Laboratory Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Cymer","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Haematology Beaumont RCSI Cancer Centre  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-1456","authenticated-orcid":false,"given":"Phillip T.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Haematology Beaumont RCSI Cancer Centre  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Thornton","sequence":"additional","affiliation":[{"name":"Department of Haematology Beaumont RCSI Cancer Centre  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"McAuley","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony","family":"Black","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2780-0878","authenticated-orcid":false,"given":"Omar","family":"Abdelzaher","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Duane","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"},{"name":"Department of Haematology Beaumont RCSI Cancer Centre  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Cichocka","sequence":"additional","affiliation":[{"name":"Blood Cancer Network Ireland University of Galway  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Szegezdi","sequence":"additional","affiliation":[{"name":"School of Biological and Chemical Sciences University of Galway  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meegahage","family":"Perera","sequence":"additional","affiliation":[{"name":"Department of Haematology Midland Regional Hospital Tullamore  Tullamore Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"Crotty","sequence":"additional","affiliation":[{"name":"Department of Haematology Midland Regional Hospital Tullamore  Tullamore Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Connolly","sequence":"additional","affiliation":[{"name":"Department of Haematology Midland Regional Hospital Tullamore  Tullamore Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Haematology Midland Regional Hospital Tullamore  Tullamore Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Clifford","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Limerick  Limerick Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-103X","authenticated-orcid":false,"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Haematology Department Galway University Hospital  Galway Ireland"},{"name":"Discipline of Advanced Therapies, School of Medicine University of Galway  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Meenaghan","sequence":"additional","affiliation":[{"name":"Haematology Department Galway University Hospital  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliy","family":"Mykytiv","sequence":"additional","affiliation":[{"name":"Department of Haematology Cork University Hospital  Cork Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3377-1130","authenticated-orcid":false,"given":"Ezzat","family":"Elhassadi","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Waterford  Waterford Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Coyne","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's University Hospital  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Cummins","sequence":"additional","affiliation":[{"name":"Molecular Pathology Laboratory Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Kuiper","sequence":"additional","affiliation":[{"name":"SkylineDx  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-7140","authenticated-orcid":false,"given":"Michael","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"Haematology Department Galway University Hospital  Galway Ireland"},{"name":"Department of Medicine University of Galway  Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan V.","family":"Glavey","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Group Royal College of Surgeons in Ireland  Dublin Ireland"},{"name":"Molecular Pathology Laboratory Royal College of Surgeons in Ireland  Dublin Ireland"},{"name":"Department of Haematology Beaumont RCSI Cancer Centre  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"8","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081961","article-title":"A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics","volume":"10","author":"Awada H.","year":"2021","journal-title":"Cells"},{"key":"e_1_2_10_3_1","unstructured":"\u201cCancer in Ireland 1994\u20132022 \u201d2022."},{"issue":"4","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/Lenalidomide\/Dexamethasone in Transplant\u2010Ineligible Newly Diagnosed Myeloma: MAIA Long\u2010Term Outcomes","volume":"39","author":"Facon T.","year":"2025","journal-title":"Leukemia"},{"issue":"10297","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B\u2010Cell Maturation Antigen\u2010Directed Chimeric Antigen Receptor T\u2010Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE\u20101): A Phase 1b\/2 Open\u2010Label Study","volume":"398","author":"Berdeja J. G.","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long\u2010Term (>\/=5\u2010Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE\u20101 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath S.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long\u2010Term Follow\u2010Up From the Phase 1\/2 MajesTEC\u20101 Trial of Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Garfall A. L.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 Update on Diagnosis, Risk\u2010Stratification, and Management","volume":"99","author":"Rajkumar S. V.","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"11","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A Gene Expression Signature for High\u2010Risk Multiple Myeloma","volume":"26","author":"Kuiper R.","year":"2012","journal-title":"Leukemia"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high\u2010risk myeloma","volume":"2010","author":"Avet Loiseau H.","year":"2010","journal-title":"Hematology Am Soc Hematol Ed Prog"},{"issue":"23","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra\u2010High\u2010Risk Multiple Myeloma","volume":"41","author":"Kaiser M. F.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High\u2010Risk Multiple Myeloma","volume":"43","author":"Avet\u2010Loiseau H.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"e_1_2_10_13_1","first-page":"1008","article-title":"Gene Expression Profiling as a Prognostic Tool in Multiple Myeloma","volume":"4","author":"Black H.","year":"2021","journal-title":"Cancer Drug Resistance"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2025029987","article-title":"Challenging the Concept of Functional High\u2010Risk Myeloma Through Transcriptional and Genetic Profiling","volume":"146","author":"Beer S. A.","year":"2025","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmoldx.2020.10.010","article-title":"Analytical Validation of SKY92 for the Identification of High\u2010Risk Multiple Myeloma","volume":"23","author":"Beers E. H.","year":"2021","journal-title":"Journal of Molecular Diagnostics"},{"issue":"24","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and Predictive Performance of R\u2010ISS With SKY92 in Older Patients With Multiple Myeloma: The HOVON\u201087\/NMSG\u201018 Trial","volume":"4","author":"Kuiper R.","year":"2020","journal-title":"Blood Advances"},{"issue":"1","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ijlh.13691","article-title":"Prognostic Gene Expression Analysis in a Retrospective, Multinational Cohort of 155 Multiple Myeloma Patients Treated Outside Clinical Trials","volume":"44","author":"Chen Y. T.","year":"2022","journal-title":"International Journal of Laboratory Hematology"},{"issue":"11","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/s41375-020-0750-z","article-title":"Predicting Ultrahigh Risk Multiple Myeloma by Molecular Profiling: An Analysis of Newly Diagnosed Transplant Eligible Myeloma XI Trial Patients","volume":"34","author":"Shah V.","year":"2020","journal-title":"Leukemia"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.820768","article-title":"Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk\u2010Adapted Treatment","volume":"12","author":"Cerchione C.","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/bjh.20050","article-title":"Enhancing Risk Stratification and Treatment Decision in Multiple Myeloma With SKY92 Gene Expression Profiling in Real\u2010World Data","volume":"206","author":"Biran N.","year":"2025","journal-title":"British Journal of Haematology"},{"issue":"3","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jha2.209","article-title":"Gene Expression Profiling Impacts Treatment Decision Making in Newly Diagnosed Multiple Myeloma Patients in the Prospective PROMMIS Trial","volume":"2","author":"Biran N.","year":"2021","journal-title":"EJHaem"},{"issue":"3","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.18211","article-title":"Real\u2010World Data on Prognostic Value of Measurable Residual Disease Assessment by Fragment Analysis or Next\u2010Generation Sequencing in Multiple Myeloma","volume":"198","author":"Cho H.","year":"2022","journal-title":"British Journal of Haematology"},{"key":"e_1_2_10_23_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.957743","article-title":"Clinical Implication of Minimal Residual Disease Assessment by Next\u2010Generation Sequencing\u2010Based Immunoglobulin Clonality Assay in Pediatric B\u2010Acute Lymphoblastic Leukemia","volume":"12","author":"Lee J. W.","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00449","article-title":"Standardized Minimal Residual Disease Detection by Next\u2010Generation Sequencing in Multiple Myeloma","volume":"9","author":"Yao Q.","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"23","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta\u2010Analysis Establishes the Role of MRD Negativity in Long\u2010Term Survival Outcomes in Patients With Multiple Myeloma","volume":"4","author":"Munshi N. C.","year":"2020","journal-title":"Blood Advances"},{"issue":"2","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmoldx.2020.10.015","article-title":"Routine Evaluation of Minimal Residual Disease in Myeloma Using Next\u2010Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison With High\u2010Sensitivity Flow Cytometry","volume":"23","author":"Ho C.","year":"2021","journal-title":"Journal of Molecular Diagnostics"},{"issue":"9","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jmoldx.2020.06.007","article-title":"High\u2010Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation\u2010Dependent Probe Amplification for Improved Standardization of in Vitro Research","volume":"22","author":"Menezes K.","year":"2020","journal-title":"Journal of Molecular Diagnostics"},{"issue":"1","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-58828-8","article-title":"TRIM33 Loss in Multiple Myeloma Is Associated With Genomic Instability and Sensitivity to PARP Inhibitors","volume":"14","author":"McAvera R. M.","year":"2024","journal-title":"Scientific Reports"},{"issue":"3","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.14352","article-title":"Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy","volume":"114","author":"McAuley N.","year":"2025","journal-title":"European Journal of Haematology"},{"issue":"1","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17124-4","article-title":"The Irish DNA Atlas: Revealing Fine\u2010Scale Population Structure and History Within Ireland","volume":"7","author":"Gilbert E.","year":"2017","journal-title":"Scientific Reports"},{"issue":"11","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response\u2010Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single\u2010Arm, Phase 2 Trial","volume":"10","author":"Costa L. J.","year":"2023","journal-title":"he Lancet Haematology"},{"issue":"5","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","article-title":"Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High\u2010Risk Multiple Myeloma: A Single\u2010Center Retrospective Study","volume":"20","author":"Kunacheewa C.","year":"2020","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma and the Impact of Daratumumab in MAIA and ALCYONE","volume":"139","author":"San\u2010Miguel J.","year":"2022","journal-title":"Blood"},{"issue":"9","key":"e_1_2_10_34_1","article-title":"Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study","volume":"7","author":"Ramasamy K.","year":"2023","journal-title":"Hema"},{"issue":"1","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2024.104261","article-title":"Minimal residual disease in multiple myeloma","volume":"54","author":"Moukalled N.","year":"2025","journal-title":"Presse M\u00e9dicale"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.20935\/AcadMolBioGen8333"},{"issue":"1","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00905-8","article-title":"Real\u2010World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Report From the Canadian Myeloma Research Group Database","volume":"13","author":"Cote J.","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-021-01140-5","article-title":"Integrative Multi\u2010Omics Identifies High Risk Multiple Myeloma Subgroup Associated With Significant DNA Loss and Dysregulated DNA Repair and Cell Cycle Pathways","volume":"14","author":"Ortiz\u2010Estevez M.","year":"2021","journal-title":"BMC Medical Genomics"},{"issue":"11","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome Instability in Multiple Myeloma","volume":"34","author":"Neuse C. J.","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_10_40_1","article-title":"NUF2 Overexpression Predicts Poor Outcomes in Multiple Myeloma","volume":"12","author":"Zhang S.","year":"2025","journal-title":"Genetic Disorders"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:57:48Z","timestamp":1786103868000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":39,"alternative-id":["10.1111\/ejh.70282"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70282","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70282"}}